GNSS vs HIT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Genasys Inc. exhibits critical financial instability, highlighted by a weak Piotroski F-Score of 2/9 and a dangerous Debt/Equity ratio of 9.35. While the company is experiencing hyper-growth in revenue (145.90% YoY), this has not translated into operational efficiency or earnings reliability, as evidenced by 0/4 earnings beats in the last year. Severe liquidity constraints (Current Ratio 0.73, Quick Ratio 0.45) and a massive Price-to-Book ratio of 45.00 suggest the stock is priced on speculative growth rather than fundamental value. The combination of high leverage and consistent earnings misses creates a high-risk profile despite the optimistic analyst target price.
HIT presents a high-risk profile characterized by a Piotroski F-Score of 4/9 (Stable) but severe technical deterioration. While the company exhibits strong revenue growth (53.10%) and an exceptionally clean balance sheet (Debt/Equity 0.01), it is trading at a massive premium to its Graham Number ($0.37) and Intrinsic Value ($0.14). The stock is currently in a freefall with a 0/100 technical trend and a 60.8% decline over the last six months, coupled with a poor earnings track record of 0/4 beats.
Compare Another Pair
Related Comparisons
GNSS vs HIT: Head-to-Head Comparison
This page compares Genasys Inc. (GNSS) and Health In Tech, Inc. (HIT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.